GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: The Oncologist, Oxford University Press (OUP), Vol. 22, No. 12 ( 2017-12-01), p. 1431-1443
    Abstract: Obesity is a consideration in the pharmacologic intervention for estrogen receptor (ER) positive (ER+) breast cancer risk. Body mass index (BMI) and waist/hip ratio (WHR) have demonstrated different effects on breast cancer risk in relation to estrogen receptor (ER) status, but the results have been inconsistent. Furthermore, the situation in Chinese women remains unclear. Materials and Methods We conducted a case-control study including 1,439 breast cancer cases in Northern and Eastern China. Both ER and progesterone receptor (PR) statuses were available for 1,316 cases. Associations between body size-related factors and breast cancer risk defined by receptor status were assessed by multiple polytomous unconditional logistic regression analysis. Results Body mass index and WHR were positively associated with overall breast cancer risk. Body mass index was positively associated with both ER+/PR positive (PR+) and ER negative (ER−)/PR negative(PR−) subtype risks, although only significantly for ER+/PR+ subtype. Waist–hip ratio was only positively correlated with ER−/PR− subtype risk, although independent of BMI. Body mass index was positively associated with risk of ER+/PR+ and ER−/PR− subtypes in premenopausal women, whereas WHR was inversely correlated with ER+/PR− and positively with ER−/PR− subtype risks. Among postmenopausal women, WHR & gt;0.85 was associated with increased risk of ER−/PR− subtype. Conclusion Both general and central obesity contribute to breast cancer risk, with different effects on specific subtypes. General obesity, indicated by BMI, is more strongly associated with ER+/PR+ subtype, especially among premenopausal women, whereas central obesity, indicated by WHR, is more specific for ER−/PR− subtype, independent of menopausal status. These results suggest that different chemoprevention strategies may be appropriate in selected individuals.
    Type of Medium: Online Resource
    ISSN: 1083-7159 , 1549-490X
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2017
    detail.hit.zdb_id: 2023829-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P1-17-02-P1-17-02
    Abstract: Background: Breast cancer is the most common cancer among women in China. Hence, how best to live with and improve the quality of life (QOL) of this growing population of women is thus becoming of great public health importance. The aim of the study was to evaluate the relationship of lifestyle habits to QOL among younger and older women who were initially diagnosed with breast cancer within the first two weeks, determine the contribution of lifestyle habits factors on QOL. Methods: A multi-center, hospital-based, case control study was conducted among breast cancer women from 21 hospitals in 11 provinces or municipalities in northern and eastern China from April 2012 to April 2013. The Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) simplified Chinese version 4 was used to measure QOL. Chi-square test, t-test and Generalized Linear Models were conducted to verify differences in QOL between two groups and to evaluate the contribution of lifestyle habits factors (including smoking, passive smoking, alcohol intake, Tea, Coffee, Sleep satisfaction, Current life satisfaction, Physical activity, BMI) on QOL of breast cancer patients. Results: 1199 eligible breast cancer patients were used for analysis as appropriate. Younger women (age & lt;50 years) at diagnosis of breast cancer appeared to be related to lower scores than older women (age ≥50 years) in QOL subscales including emotional well being (p=0.003), functional well being (p=0.006), breast cancer subscale (p=0.038), and FACT-B Total scores (p=0.028). The relationships of the 9 lifestyle habit items to QOL were different between younger and older women. Firstly, very satisfied to sleep satisfaction and current life satisfaction at diagnosis were associated with higher scores in all the women with breast cancer. Secondly, tea (p=0.009) and alcohol drinking (p=0.001) women showed a significantly higher score in younger age group, while drink coffee (p=0.009) showed a significantly lower score in older age group. Thirdly, compare to the younger age group, often participate in physical activities in older age group was associated with higher QOL overall (p=0.002). And smoking showed worse QOL in the older age group (p=0.045). No other significant items of lifestyle habits were observed associated with FACT-B Total scores. Generalized Linear Models were estimated for the total FACT-B score to identify characteristics that were most strongly associated with these QOL scores. Conclusion: Younger patients ( & lt;50 years) showed significantly lower QOL than older patients (≥50 years). Tea and alcohol drinking, very satisfied to sleep satisfaction and current life satisfaction were the strongest predictors of higher QOL in China women when diagnosed with breast cancer at younger age. Meanwhile, no coffee, often participate in physical activities and very satisfied to sleep satisfaction and current life satisfaction were the key predictors of higher QOL in older breast cancer women. Focusing on those predictors may present an especially worthwhile endeavor to enhance the long-term breast cancer survivors’ QOL. The mean scores of the FACT-B Total between two age groupsVariable & lt;50≥50Scores(mean)PScores(mean)PCigarette smoking0.0500.045Yes91.10±17.02977.67±15.080No83.80±16.41885.79±16.894Passive smoking0.0580.722Yes82.59±16.53185.61±16.851No85.67±17.57786.43±18.928Alcohol drinking0.0010.662Yes89.06±19.72986.23±17.958No83.26±15.82085.17±16.834Tea0.0090.053Yes87.22±16.17888.31±18.895No83.21±16.51084.55±16.447Coffee0.0970.009Yes88.81±18.54175.50±10.081No83.77±16.44485.70±17.150Sleep satisfaction0.0010.012Very satisfied89.63±17.63389.69±18.659Satisfied82.67±15.89483.68±15.668Dissatisfied84.89±16.87888.15±18.804Current life satisfaction & lt;0.001 & lt;0.001Very satisfied89.10±19.50593.05±20.578Satisfied84.75±15.73586.57±16.390Dissatisfied79.24±15.84077.41±14.562Physical activity0.0550.002Often83.93±17.14589.51±19.928Occasionally85.53±17.02384.97±16.064Never82.01±14.88782.36±14.589BMI (kg/m2) 0.1370.239 & lt;24.084.73±16.41785.97±17.51624.0-28.082.25±15.85984.52±15.862 & gt;28.084.82±17.04588.41±17.180 Generalized Linear Models ResultsVariableBS.E.95% C.I.walddfPLowerUpper & lt;50Alcohol drinking6.0301.78432.5339.52711.42310.001Tea3.5241.52180.5416.5075.36310.021Very satisfied to Sleep satisfaction4.6042.26340.1689.0404.13710.042Very satisfied to Current life satisfaction9.3762.24594.97413.77817.4291 & lt;0.001≥50Coffee-9.4623.6877-16.609-2.2346.58310.010Often participate in physical activities7.1161.97803.23910.99312.9431 & lt;0.001Very satisfied to Sleep satisfaction4.0951.96180.2507.9404.35810.037Very satisfied to Current life satisfaction15.4383.26238.95421.74222.1341 & lt;0.001 Citation Format: Chao Zheng, Liyuan Liu, Shude Cui, Fuguo Tian, Zhimin Fan, Cuizhi Geng, Xuchen Cao, Zhenlin Yang, Xiang Wang, Hong Liang, Shu Wang, Hongchuan Jiang, Xuening Duan, Haibo Wang, Guolou Li, Qitang Wang, Jianguo Zhang, Feng Jin, Jinhai Tang, Liang Li, Shiguang Zhu, Wenshu Zuo, Fei Wang, Lixiang Yu, Fei Zhou, Yujuan Xiang, Mingming Guo, Yongjiu Wang, Shuya Huang, Zhongbing Ma, Liang Li, Dezong Gao, Qiang Zhang, Qinye Fu, Zhigang Yu. Relationship of lifestyle habits to quality of life of recently diagnosed breast cancer between younger and older women in China [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-17-02.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 5_Supplement ( 2023-03-01), p. P4-03-31-P4-03-31
    Abstract: Objective: Benign breast disease (BBD), especially benign proliferative breast disease (BPBD), is related to increased breast cancer risk. However, few studies have examined whether conventional breast cancer risk factors influence risk of breast cancer among women with BBD. The aim of this study was to evaluate the associations of lifestyle factors with risk of breast cancer among women biopsied for BBD within a multi-center, hospital-based, case-control study in China, in order to provide scientific basis of health guidance for BBD patients and lay the foundation for primary prevention of breast cancer. Methods: A multi-center, hospital-based, case-control study was conducted. Patients with BPBD (n=608) and patients with non-proliferative breast disease (NPBD) (n=366) were collected from 23 hospitals in 11 provinces during April 2012 to April 2013. A face-to-face survey, baseline data and fasting blood was collected with all study subjects. Serum adiponectin levels were assayed using ELISA. After 10 years, the cumulative incidence rate of breast cancer in the two groups was counted through follow-up. Logistic regression analysis was used to obtain the association between specific factors and risk of breast cancer. Results: After 10 years’ follow-up, 388 BPBD and 240 NPBD cases were included in the final analysis (Table 1), of which 16 (4.12%) and 3 (1.25%) developed breast cancer, respectively. The cumulative incidence of breast cancer between the two groups was significant difference (P=0.041). Compared with women in the NPBD group, BPBD group were more likely to be central obesity (with higher waist-to-hip ratio (WHR)) (OR 24.98, 95% CI 1.845-336.203, P=0.015) and less likely to have physical activity (OR 0.626, 95% CI 0.416-0.943, P=0.025) and less often to eat carrots (OR 0.616, 95% CI 0.398-0.953, P=0.030) (Table 2). Subgroup analyze indicated that, physical activity, eat carrots and ham sausage, body weight, BMI, waist circumference and WHR were statistical differences in premenopausal BPBD patients, while only physical activity (OR 0.423, 95% CI 0.269-0.665 P & lt; 0.001) was the independent risk factors. Meanwhile, among the factors of Tea consumption, Glycemia, Body weight, BMI, Waist circumference, WHR and HMW/total adiponectin ratio in postmenopausal group, only HMW/total adiponectin ratio (OR 0.041, 95% CI 0.002-0.820 P=0.037) was statistically significant factor. These stratified multivariate logistic regression analysis results are shown in Table 3. Conclusion: In patients with BBD, physical activity may be the protect factor for breast cancer carcinogenesis in premenopausal women while lower HMW/total adiponectin ratio is a risk factor for postmenopausal women, which can provide direction for primary prevention of breast cancer. Table 1. Pathological types of all subjects. Table 2. The results of multivariate Logistic regression analysis. Table 3. Stratified multivariate Logistic regression analysis by menopause status. Citation Format: Chao Zheng, Dandan Ma, Linfeng Zhao, Maolin Guo, Shude Cui, Fuguo Tian, Zhimin Fan, Cuizhi Geng, Xuchen Cao, Zhenlin Yang, Xiang Wang, Hong Liang, Shu Wang, Hongchuan Jiang, Xuening Duan, Haibo Wang, Guolou Li, Qitang Wang, Jianguo Zhang, Feng Jin, Jinhai Tang, Liang Li, Shi-Guang Zhu, Wenshu Zuo, Fei Wang, Lixiang Yu, Fei Zhou, Yujuan Xiang, Mingming Guo, Yongjiu Wang, Wenzhong Zhou, Shuya Huang, Zhaohui Li, Yajie Zhou, Lijuan Hou, Xinyi Yang, Xuan Zhang, Liyuan Liu, Zhigang Yu. Lifestyle factors are associated with breast cancer risk in women biopsied for benign breast diseases in China: 10-year results of a multi-center, hospital-based, case-control study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-03-31.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Cellular Biochemistry, Wiley, Vol. 120, No. 7 ( 2019-07), p. 12039-12050
    Abstract: Breast cancer (BC) risk, development, and prognosis were closely related to obesity, diabetes mellitus, and metabolic syndrome. Protein tyrosine phosphatase, non‐receptor type 1 (PTPN1) located on chromosome 20q13, could negatively regulate insulin and leptin signaling. In this study, we determined the association of PTPN1 polymorphisms with BC risk. Methods We analyzed the distribution of 11 selected PTPN1 single nucleotide polymorphisms in Chinese female patients with BC (n = 953) and healthy controls (n = 963) based on a multicenter case‐control study. The association of PTPN1 genotypes and haplotypes frequencies with BC risk were determined by logistic regression analysis. Analyses were further stratified by body mass index (BMI), waist‐hip rate (WHR), diabetes mellitus history, and fasting plasma glucose level. The eQTL (expression Quantitative Trait Loci) analysis for PTPN1 was conducted by GTEx database. Results There were significant differences between BC cases and control groups in menopausal status, number of births, and BMI. Four single nucleotide polymorphisms (SNPs; rs3215684, rs3787345, rs718049, and rs718050) decreased overall BC risk, and other seven SNPs showed no significant association with BC risk. In multivariate analysis, BMI and rs3215684 DT + DD genotype were identified as independent risk factors for BC, and mutated genotypes of rs3215684 were correlated with increased PTPN1 expression. There are no haplotypes showed different frequencies between cases and controls. In the stratified analysis, rs2206656 showed a significant association with decreased BC risk in the subgroup of BMI ≤ 24 kg/m 2 , while rs3215684 and rs718049 showed lower BC risk in the subgroup of WHR  〉  0.85. Seven SNPs showed lower BC risk in the subgroup with diabetes mellitus history and/or fasting plasma glucose level ≥ 7 mM, while rs754118 decreased BC risk in the subgroup of fasting plasma glucose level  〈  7 mM. Conclusion Our findings suggest that PTPN1 SNPs associated with BC susceptibility in Chinese females, which also suggested a novel mechanism between obesity, diabetes mellitus, and BC risk.
    Type of Medium: Online Resource
    ISSN: 0730-2312 , 1097-4644
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2019
    detail.hit.zdb_id: 1479976-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Frontiers in Endocrinology, Frontiers Media SA, Vol. 11 ( 2020-6-4)
    Type of Medium: Online Resource
    ISSN: 1664-2392
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2020
    detail.hit.zdb_id: 2592084-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Frontiers Media SA ; 2020
    In:  Frontiers in Endocrinology Vol. 10 ( 2020-1-21)
    In: Frontiers in Endocrinology, Frontiers Media SA, Vol. 10 ( 2020-1-21)
    Type of Medium: Online Resource
    ISSN: 1664-2392
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2020
    detail.hit.zdb_id: 2592084-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    Frontiers Media SA ; 2022
    In:  Frontiers in Oncology Vol. 12 ( 2022-2-10)
    In: Frontiers in Oncology, Frontiers Media SA, Vol. 12 ( 2022-2-10)
    Abstract: Leptin (LEP) plays a physiological role through its specific receptor (LEPR) and is involved in the occurrence and development of breast cancer. Our current study aimed at determining the influence of single-nucleotide polymorphisms (SNPs) in the genes coding for LEP and LEPR on breast cancer risk. Methods In the present study, 963 breast cancer cases and 953 controls were enrolled. Five SNPs of LEP and two of LEPR were chosen to evaluate the correlation of selected SNPs with breast cancer susceptibility among women in northern and eastern China. Analyses were further stratified by body mass index (BMI), waist–hip rate (WHR), estrogen receptor, and progesterone receptor status. The expression patterns of risk variant-associated genes were detected by expression quantitative trait locus (eQTL) analysis with eQTLGen and The Cancer Genome Atlas database. Results There were significant differences between breast cancer cases and control groups in the menopausal status and family history of breast cancer. Two SNPs (rs1137101 and rs4655555) of the LEPR gene decreased overall breast cancer risk, and other five SNPs showed no significant association with breast cancer risk. rs1137101 (GA vs. GG; adjusted OR = 0.719, 95% CI = 0.578–0.894, p = 0.003) and rs4655555 (TT vs. AA; adjusted OR = 0.574, 95% CI = 0.377–0.873, p = 0.009) significantly decreased breast cancer risk after Bonferroni correction for multiple testing. In subgroup analyses, the GA and GA + AA genotypes of LEPR rs1137101 associated with decreased breast cancer risk in the subgroup of BMI ≤ 24 kg/m 2 or WHR ≥ 0.85 after Bonferroni correction. Furthermore, we found that the expressions of rs4655555-associated gene LEPR and leptin receptor overlapping transcript (LEPROT) were upregulated in breast cancer tumor tissues compared with adjacent normal tissues, and a higher expression of LEPR in tumor tissues was correlated with poor prognosis of breast cancer patients using The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) data. Conclusion Our study demonstrated that the polymorphisms rs1137101 and rs4655555 located in the LEPR gene decreased breast cancer risk in Chinese females, which might be a research-worthy bio-diagnostic marker and applied for early prediction and risk assessment of breast cancer.
    Type of Medium: Online Resource
    ISSN: 2234-943X
    Language: Unknown
    Publisher: Frontiers Media SA
    Publication Date: 2022
    detail.hit.zdb_id: 2649216-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 4_Supplement ( 2022-02-15), p. P2-13-40-P2-13-40
    Abstract: Background: Pyrotinib, a newly-developed irreversible pan-ErbB inhibitor, has shown promising antitumor activity and acceptable tolerability in phase 1-3 studies. However, findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. Herein, we conducted this multicenter real-world study to examine the treatment patterns, effectiveness and safety of pyrotinib-based therapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients in China.Methods: This is a China-based, observational study of HER2-positive BC patients receiving pyrotinib-based therapy (NCT04158505). Both early stage and advanced disease were included. Demographics, treatment patterns, and diarrhea management were summarized. The data cutoff date was April 30, 2021, and the study is ongoing to enroll. Real-world progression-free survival (PFS) and overall survival (OS) will be analyzed. Results: Between October 2019 and April 2021, a total of 907 patients (45 in the neoadjuvant setting [median age, 51 years] and 862 in the advanced setting [median age, 54 years] ) from 65 sites received at least one dose of pyrotinib. Considering the limited sample size of early stage patients so far, we focused on advanced BC patients in this report. Of 862 patients with advanced disease, 44.2% had visceral metastases, 12.5% had brain metastases, 31.1%, 35.7%, and 33.2% received pyrotinib-based therapy as first-line, second-line, and third- or later-line treatment, respectively. The majority of patients (82.5%) were trastuzumab-exposed, and 10.2% were lapatinib-treated before receiving pyrotinib. Among 744 patients with available treatment information, 75.8% started with standard dose of pyrotinib (400 mg). Pyrotinib plus capecitabine (372 [50.0%]) was the most commonly used regimen for advanced disease, followed by pyrotinib plus chemotherapy other than capecitabine (189 [25.4%] ), pyrotinib plus trastuzumab and chemotherapy (100 [13.4%]), and pyrotinib alone (77 [10.3%] ). At the time of data cutoff, there were 164 (19.0%) progression or death events in 862 patients with advanced disease, and the median PFS and OS was not mature for the whole population. The median PFS for patients receiving second-line pyrotinib-based therapy was 11.7 months (95% CI, 8.8-not reached). The most common adverse event was diarrhea. Any grade and grade ≥3 diarrhea occurred in 70.5% and 14.9% of 907 patients, respectively. Diarrhea in eight (0.9%) patients with advanced disease were deemed as serious adverse events. Eighty-nine (9.8%) patients received diarrhea prophylaxis, and 436 (48.1%) used antidiarrhea drugs after diarrhea occurred. Montmorillonite powder (6.0% and 33.6%) were the most commonly used drug for both diarrhea prophylaxis and treatment, followed by loperamide (3.9% and 27.9%).Conclusions: In real world, a high percentage of physicians chose to use pyrotinib-based therapy in front lines when treating HER2-positive advanced BC patients, which might maximize its antitumor activity. Diarrhea is manageable in the real-world setting. Citation Format: Yiqun Li, Zhongsheng Tong, Quchang Ouyang, Xinhong Wu, Wei Li, Li Cai, Zhiyong Yu, Zhengxiang Han, Xiaojia Wang, Man Li, Jin Yang, Li Li, Zhaofeng Niu, Haibo Wang, Qitang Wang, Yi Li, Yuee Teng, Shiguang Zhu, Binghe Xu. Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-40.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: International Journal of Cancer, Wiley, Vol. 153, No. 10 ( 2023-11-15), p. 1809-1818
    Abstract: Pyrotinib, an irreversible pan‐ErbB inhibitor, has been approved for treating HER2‐positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real‐world data of pyrotinib‐based therapy in this population. Patients from 61 sites across China were included. Pyrotinib‐based regimens were prescribed at local physician's discretion. Demographics, treatment patterns, prognosis and safety were evaluated. The primary outcome was real‐world progression‐free survival (rwPFS). Of 1129 patients, pyrotinib‐based therapy was prescribed as first‐, second‐ and third‐ or later‐line treatment in 437 (38.7%), 476 (42.2%) and 216 (19.1%) patients, respectively. Median rwPFS (mrwPFS) was 14.3 (95% CI, 13.3‐15.2) months in the total population, with the longest mrwPFS of 17.8 (95% CI, 15.2‐24.9) months in the first‐line setting, followed by 14.4 (95% CI, 12.9‐15.3) months in the second‐line setting. Patients with third‐ or later‐line treatment also achieved a mrwPFS of 9.3 (95% CI, 8.4‐11.8) months. Patients with trastuzumab‐ or trastuzumab‐pertuzumab‐treated disease achieved a mrwPFS of 14.3 and 13.6 months, respectively. Dual HER2 blockade with pyrotinib plus trastuzumab showed a mrwPFS of 16.2 months in the total population, with data not mature in the first‐line setting. For patients with baseline brain metastases, the mrwPFS was 11.7 months. The most common adverse event was diarrhea (any grade, 73.5%; grade ≥ 3, 15.3%). In real world, pyrotinib‐based therapy shows promising effectiveness in the first‐, as well as second‐ and later‐line treatment, with acceptable tolerability. Further investigations regarding front‐line use or novel combinations of pyrotinib might facilitate to maximize its anti‐tumor potential.
    Type of Medium: Online Resource
    ISSN: 0020-7136 , 1097-0215
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 218257-9
    detail.hit.zdb_id: 1474822-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Nanoscale, Royal Society of Chemistry (RSC), Vol. 8, No. 2 ( 2016), p. 1123-1132
    Type of Medium: Online Resource
    ISSN: 2040-3364 , 2040-3372
    Language: English
    Publisher: Royal Society of Chemistry (RSC)
    Publication Date: 2016
    detail.hit.zdb_id: 2515664-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...